How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) issued its quarterly earnings results on Monday, February, 10th. The company reported $5.22 EPS for the quarter, topping analysts' consensus estimates of $4.57 by $0.65. The business had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.09 billion. Allergan had a positive trailing twelve-month return on equity of 8.46% and a negative net margin of 15.44%. Allergan's quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company posted $4.29 earnings per share.

Is Allergan a good dividend stock?

Allergan (NYSE:AGN) pays an annual dividend of $2.96 per share and currently has a dividend yield of 1.53%. The dividend payout ratio is 16.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AGN will have a dividend payout ratio of 16.33% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for AGN .

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , BlackRock (BLK) , Chipotle Mexican Grill (CMG) , Athabasca Oil (ATH) , Micron Technology (MU) , Aegean Marine Petroleum Network (ANW) , NIC (EGOV) , United Rentals (URI) and Transocean (RIG) .

NYSE:AGN

Allergan (AGN) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free AGN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $191.64
▼
$193.38
50-Day Range: $184.04
▼
$193.89
52-Week Range: $114.27
▼
$202.21

Volume: 12.44 million shs
Average Volume: 4.01 million shs
Market Capitalization: $63.50 billion

P/E Ratio: N/A
Dividend Yield: 1.53%
Price Target: N/A

Stock Analysis

Get Allergan alerts:

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Allergan Stock (NYSE:AGN)

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

AGN Stock News Headlines

April 11, 2024 | finance.yahoo.com

Allergan Aesthetics and University Lab Partners Announce the Golden Ticket Pitch Competition to Accelerate Aesthetics Start-Ups

April 5, 2024 | uk.investing.com

Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 26, 2024 | finance.yahoo.com

Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics

February 28, 2024 | finance.yahoo.com

Dr. Ran Y. Rubinstein Has Been Named Top 500 Allergan Aesthetic 2024

January 23, 2024 | in.investing.com

Pro Research: Wall Street eyes AbbVie's growth and pipeline potential

January 23, 2024 | finance.yahoo.com

Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.

January 18, 2024 | finance.yahoo.com

BodyLase® Med Spa Ends 2023 Among Top 50 Allergan Providers

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

January 4, 2024 | reuters.com

Botox rival Revance loses bid to dismiss Allergan trade secrets lawsuit

December 29, 2023 | za.investing.com

Pro Research: Wall Street explores AbbVie's market dynamics

December 26, 2023 | za.investing.com

Pro Research: wall street dives into abbvie's growth potential

December 19, 2023 | finance.yahoo.com

Dr. Ran Y. Rubinstein: Revolutionizing Aesthetics for 18 Years as an Expert Allergan and Galderma Trainer

October 24, 2023 | markets.businessinsider.com

Allergan Announces Positive Results From Phase 3 Studies Of TrenibotulinumtoxinE In Glabella Lines

October 19, 2023 | finance.yahoo.com

Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project

October 18, 2023 | finance.yahoo.com

Allergan Aesthetics and University Lab Partners Announce the Golden Passport Pitch Competition to Accelerate Aesthetics Start-Ups

October 10, 2023 | msn.com

Unlocking Vision Wellness: Allergan’s Media Conclave On World Sight Day Spotlights Eyecare's Crucial Role In Modern Workplace

September 15, 2023 | thestreet.com

Allergan (AGN), Pfizer in Advanced Takeover Talks, Stocks Fall, Jim Cramer Weighs In

August 2, 2023 | ca.investing.com

Bausch + Lomb's Saunders doesn't expect more big deals in the near term

August 2, 2023 | za.investing.com

Bausch + Lomb posts better than expected Q2 earnings

August 1, 2023 | finance.yahoo.com

Allergan Aesthetics Announces First Ever JUVÉDERM® Day

July 24, 2023 | thestreet.com

Why Valeant Pharmaceuticals (VRX) Stock Is Up

July 7, 2023 | thestreet.com

Cramer -- Why a Pfizer Merger With Allergan Makes Sense

June 9, 2023 | msn.com

N.C. to receive $521M in opioid settlements with Teva, Allergan, CVS and Walgreens

June 9, 2023 | msn.com

Virginia receives $365.6 million in opioid settlements with Teva, Allergan, CVS, and Walgreens

May 22, 2023 | thestreet.com

Pfizer (PFE) Stock Sinks, Negotiating Break-Up Fee in Allergan Deal, Jim Cramer's View

May 17, 2023 | marketwatch.com

Bipolar Disorder Therapeutics Market Size, Growth Opportunities, Future Trends and Share with Revenue Forecast 2028

See More Headlines

Receive AGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergan and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/10/2020
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NYSE:AGN
Previous Symbol: NYSE:ACT
CUSIP: 01849010
CIK: 1578845
Web: www.allergan.com
Phone: 862-261-7000
Fax: N/A
Employees: 17,400
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $17.64
Trailing P/E Ratio: N/A
Forward P/E Ratio: 11.56
P/E Growth: 1.63
Net Income: $-5,271,000,000.00
Net Margins: -15.44%
Pretax Margin: N/A
Return on Equity: 8.46%
Return on Assets: 5.31%

Debt

Debt-to-Equity Ratio: 0.31
Current Ratio: 1.01
Quick Ratio: 0.84

Sales & Book Value

Annual Sales: $16.09 billion
Price / Sales: 3.95
Cash Flow: $36.70 per share
Price / Cash Flow: 5.26
Book Value: $177.28 per share
Price / Book: 1.09

Miscellaneous

Outstanding Shares: 329,002,000
Free Float: N/A
Market Cap: $63.50 billion
Optionable: Optionable
Beta: 1.20

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Brenton L. Saunders (Age 49)
Chairman, Pres & CEO
Mr. William Meury (Age 51)
Exec. VP & Chief Commercial Officer
Dr. C. David Nicholson (Age 64)
Exec. VP and Chief R&D Officer
Mr. Matthew M. Walsh (Age 52)
Exec. VP & CFO
Mr. Wayne R. Swanton (Age 51)
Exec. VP of Global Operations

Key Competitors

View All Competitors

Should I Buy Allergan Stock? AGN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Allergan plc:

Allergan plc is a well-established pharmaceutical company with a diverse portfolio of branded pharmaceuticals, devices, biologics, and surgical products.
Recent developments in research and development have led to the creation of innovative and potentially lucrative products.
The company has a strong track record of successful mergers and acquisitions, which could lead to further growth and expansion.
Investors may find the current stock price of Allergan plc to be attractive for potential gains in the future.
Allergan plc has a global presence, providing opportunities for revenue growth in various markets.

Cons

Investors should be bearish about investing in Allergan plc for these reasons:

While the company has a diverse portfolio, it also means that there is increased competition in the pharmaceutical industry.
Regulatory challenges and changes in healthcare policies could impact the company's profitability and operations.
Fluctuations in currency exchange rates may affect Allergan plc's financial performance, especially in international markets.
The pharmaceutical industry is subject to rapid technological advancements and changes, which could impact the relevance of Allergan plc's products.
Investors should carefully consider the risks associated with investing in a company that operates in a highly regulated and competitive industry.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Allergan pros and cons to contact@marketbeat.com.

AGN Stock Analysis - Frequently Asked Questions

How were Allergan's earnings last quarter?: Allergan plc (NYSE:AGN) issued its quarterly earnings results on Monday, February, 10th. The company reported $5.22 EPS for the quarter, topping analysts' consensus estimates of $4.57 by $0.65. The business had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.09 billion. Allergan had a positive trailing twelve-month return on equity of 8.46% and a negative net margin of 15.44%. Allergan's quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company posted $4.29 earnings per share.
Is Allergan a good dividend stock?: Allergan (NYSE:AGN) pays an annual dividend of $2.96 per share and currently has a dividend yield of 1.53%. The dividend payout ratio is 16.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AGN will have a dividend payout ratio of 16.33% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AGN.
What other stocks do shareholders of Allergan own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

This page (NYSE:AGN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Allergan (AGN) Stock Price, News & Analysis

About Allergan Stock (NYSE:AGN)

AGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Should I Buy Allergan Stock? AGN Pros and Cons Explained

Pros

Cons

AGN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info